Other stars in December included Orthocell (ASX:OCC), which was up 67% amid “outstanding” clinical trial results and expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback